Shots:
- The EMA has granted approval to the company’s Avzivi (bevacizumab), a biosimilar version of Avastin. Sandoz is responsible for marketing the drug across the EU
- The license and commercialization agreement b/w Bio-Thera and Sandoz was signed in Sep 2021, under which Bio-Thera had the development and manufacturing rights while Sandoz secured the commercialization rights worldwide
- Avzivi is a humanized mAb that works by inhibiting the binding of VEGF with its receptors to reduces neovascularization & induce blood vessels degradation, inhibiting tumor growth
Ref: Bio-Thera | Image: Bio-Thera| Press Release
Related News:- Dr. Reddy’s Ituxredi (Biosimilar, MabThera) Receives the CHMP’s Positive Opinion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
